Rebound Insomnia: A Critical Review
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
Rebound insomnia, a worsening of sleep compared with pretreatment levels, has been reported upon discontinuation of short half-life benzodiazepine hypnotics. This paper reviews the existing sleep laboratory studies for the presence or absence of rebound insomnia following treatment with triazolam, temazepam, and flurazepam in insomniac patients or poor sleepers and, when possible, in normals. The results indicate that rebound insomnia is a distinct possibility after discontinuation of triazolam in both insomniacs and normal controls. Compared with baseline, disturbed sleep was reported in insomniacs or poor sleepers for the first 1 or 2 nights of withdrawal in seven of nine polygraphically recorded sleep studies following triazolam 0.5 mg and in one of two studies following triazolam 0.25 mg. In one study conducted in normal volunteers, rebound insomnia was observed following triazolam 0.5 mg but not triazolam 0.25 mg. In another study, which used subjective reports of sleep rather than polygraphic recordings, rebound insomnia was significantly attenuated after triazolam 0.5 mg by tapering the dose over 4 nights. The risk of rebound insomnia after temazepam 15 or 30 mg was low. In keeping with its long elimination half-life, flurazepam (30 mg) continued to exert beneficial effects for the first 2-3 withdrawal nights, but the possibility of a mild rebound insomnia cannot be dismissed during the intermediate withdrawal period (nights 4-10) following prolonged, consecutive, nightly administration (more than 30 nights). The benzodiazepine hypnotics are generally preferred over other types (barbiturates or nonbenzodiazepine, nonbarbiturate), but there are advantages and disadvantages related to half-life of the benzodiazepines. The risk of rebound insomnia is greater with the short half-life as compared with the long half-life benzodiazepines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These symptoms are more severe following withdrawal from short rather than long half-life BZDs [39,40,41,42,43].”
From Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders (2021) · cites this paper as [43]
In the citing paper
“Studies assessing the effect of abrupt versus gradual withdrawal [43,53,54,55,56] show that the withdrawal syndrome observed in the case of abrupt discontinuation makes it very difficult to stop the use of these molecules, especially in the case of short half-life BZDs. These studies recommend reducing BZD consumption over a period of at least 4 weeks.”
From Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders (2021) · cites this paper as [43]
Citations
Cites
Still being checked.
Cited by
Classification of Sleep Disorders
Thorpy, M. J. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0145-6 · Cited by 444
Morin, C. M., Bastien, C., Guay, B., Radouco-Thomas, M., Leblanc, J., & Vallières, A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.332 · Cited by 348
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15174 · Cited by 294
Residual Effects of Hypnotics: Epidemiology and Clinical Implications
Vermeeren, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00003 · Cited by 277
Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem: Therapeutic Implications
Salvà, P., & Costa, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00002 · Cited by 273
Metadata
- Authors
- GILLIN, J. C., SPINWEBER, C. L., & JOHNSON, L. C.
- Affiliations
- University of California San Diego (US)
- Naval Health Research Center (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1989-06
- Volume
- 9
- Issue
- 3
- Pages
- 161???172
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2043451114
- Cited by
- 99
- References
- 0
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- rebound insomnia, benzodiazepine withdrawal, triazolam, temazepam, flurazepam, insomnia treatment, dose tapering, sleep disorders
- MeSH terms
- Flurazepam, Humans, Sleep Initiation and Maintenance Disorders, Sleep Stages, Substance Withdrawal Syndrome, Temazepam, Anti-Anxiety Agents, Triazolam
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rebound Insomnia: A Critical Review. https://app.cochat.ai/papers/10.1097/00004714-198906000-00002
- The paper
- GILLIN, J. C., SPINWEBER, C. L., & JOHNSON, L. C. (1989). Rebound Insomnia: A Critical Review. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198906000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.